Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "FKBP" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
FKBP, or FK506 binding protein, is a family of proteins that have prolyl isomerase activity and are related to the cyclophilins in function, though not in amino acid sequence. FKBPs have been identified in many eukaryotes, ranging from yeast to humans, and function as protein folding chaperones for proteins containing proline residues. Along with cyclophilin, FKBPs belong to the immunophilin family.
Method for regulating protein function in cells using synthetic small molecules
Methods and compositions for the rapid and reversible destabilizing of specific proteins using cell-permeable, synthetic molecules are described. Stability-affecting proteins, e.g., derived from FKBP and DHFR proteins are fused to a protein of interest and the presence or absence of the ligand is used to modulate the stability of the fusion protein.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor
The present invention provides compositions and methods for evaluating the likelihood that a tumor is sensitive to an mTOR inhibitor, e.g., rapamycin or a rapamycin analog. The invention provides FKBP proteins as biomarkers for predicting the likelihood that a tumor is sensitive to an mTOR inhibitor. The methods include assessing the expression or activity of an FKBP protein, e.g., FKBP 12, in a subject with a tumor or in a sample derived from a tumor. Additional biomarkers and biomarker combinations are also provided. The invention also provides kits containing, e.g., a validated antibody or ligand for assessing the expression or activity of an FKBP protein.
Owner:ARIAD PHARMA INC
Method for regulating protein function in cells using synthetic small molecules
Methods and compositions for the rapid and reversible destabilizing of specific proteins using cell-permeable, synthetic molecules are described. Stability-affecting proteins, e.g., derived from FKBP and DHFR proteins are fused to a protein of interest and the presence or absence of the ligand is used to modulate the stability of the fusion protein.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
FKBP-L And Uses Thereof
Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and / or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
Owner:ALMAC DISCOVERY LIMITED
FKBP-L and uses thereof
Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and / or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
Owner:ALMAC DISCOVERY LIMITED
p27 (Kip1) -FKBP-12 protein complexes
The present invention is directed to complexes of the protein p27(Kip1) with proteins identified as interacting with p27(Kip1) by a yeast mating test. Specifically, the present invention is directed to complexes with p27(Kip1) and FKBP-12. The present invention is also directed to complexes of a derivative, fragment or analog of p27(Kip1) and a derivative, fragment or analog of FKBP-12. Methods of screening the complexes for efficacy in treating and / or preventing certain diseases and disorders, particularly hyperproliferative disorders, including cancer, neurodegenerative disease, autoimmune disease, are also provided.
Owner:NANDABALAN KRISHNAN +1
Chimeric fusion protein
The invention discloses the cloning, expression and uses of a chimeric fusion protein with superior chaperone and folding activities compared to the wild type chaperones. This invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule comprising nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for an FK506 binding protein (FKBP) or an FK506-binding-protein-like domain (FKBP-like domain). In particular, this invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule comprising nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for a human FKBP type peptidyl-prolyl-cis / trans isomerase (PPIase), methods of producing these chimeric fusion proteins and their uses as folding helpers in the production of other proteins and in the process of the production of vaccines or pharmaceuticals, and as folding helpers for performing immunoassays.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Rapamycin analogues and their pharmaceutical use
Novel rapamycin analogues and methods for their production with FKBP and / or MIP inhibitory activity with reduced mTOR inhibitory activity with therapeutic potential e.g. as bacterial virulence inhibitors.
Owner:ISOMERASE THERAPEUTICS
Inductive base editing system and application thereof
ActiveCN112877314ASave editing timeReduce off-target editingHydrolasesDNA/RNA fragmentationCytosine deaminaseBase J
The invention discloses an inducible base editing system and an application thereof. The base editing system is composed of inducible human source cytosine deaminase (A3A) and SpCas9 with single nick activity; the deaminase can be split on the basis of potential amino acid sites; rapamycin interacts with the N end and the C end of the amino acid resolution site through FRB / FKBP to recombine split deaminase, and basic group editing is completed through induction. According to the method, the base editing activity is controlled by constructing the inducible base editing system, so that off-target editing is reduced; meanwhile, the splitting design in the application does not reduce target editing, so that the splitting design can be used as a compensation strategy of protein mutation, and can be used in combination with the mutated deaminase to further reduce off-target editing.
Owner:SICHUAN UNIV
Methods of screening for agents that promote nerve cell growth
InactiveUS6852496B1Promote cell growthEffective stimulationCompounds screening/testingBiocideFKBPNerve cells
Analogs of FK506 that do not bind FKBP-12 have been found to effectively promote nerve cell growth and regeneration, thereby speeding functional recovery of damaged nervous tissue and axonal regeneration without causing immunosuppression.
Owner:OREGON HEALTH & SCI UNIV
Vector system for inducing apoptosis
The invention relates to the field of biomedicine, and discloses a vector system for inducing apoptosis, wherein the vector system comprises Plasmid CMV-FKBP-tdTomato and Plasmid EF1[alpha]-FRBCaspase8-2A-BSD. The invention further discloses a preparation method of the vector system. The invention also discloses an application of the vector system. The vector system is simple in preparation process, can be locally imported and expressed at a specific part, is direct in system action and lesion organism method, is short in onset period, can shorten the research time, can independently control the marking and clearing processes, and is more intuitive in experiment result; therefore, the vector system disclosed by the invention can be widely applied to mechanism research and treatment strategy exploration of diseases, such as in-vivo lesion cell distribution research of the diseases and occurrence and treatment relationship research of lesion cells and the diseases.
Owner:GUIZHOU MEDICAL UNIV
Establishment method of programmed necrosis inducing system
The invention discloses an establishment method of a programmed necrosis inducing system. The establishment method comprises the following steps: linking a target gene segment RIPK3-2*FKBP to lentiviral vector containing a Tet-On system, so that a system which can induce expression is constructed; co-transfecting a vector which is correctly sequenced and a lentiviral element vector into 293T cells, collecting virus liquid infected Hela cells and A549 cells, and implementing puromycin screening, so that a stable cell line is obtained; inducing stable expression of RIPK3-2*FKBP protein of the cells by adding doxycycline to a culture medium, and then adding a dimer so as to induce dimerization of RIPK3; and on the basis of Western blotting and related experimental technological means, analyzing an experimental result. The inducing system provided by the invention has the beneficial effects that programmed necrosis of cells is induced through the Dox (the doxycycline) and Idimer; the system is higher in sensitivity and efficiency and stronger in specification; and necrosis of the cells can be rapidly induced.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Compounds that participate in cooperative binding and uses thereof
The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity.
Owner:REVOLUTION MEDICINES INC
Methods to identify modulators of RyR calcium channels
ActiveUS10281476B2Highly parallel biological researchQuick analysisDisease diagnosisBiological testingFKBPEnergy transfer
Provided herein are methods for identifying a compound that modulates a Ryanodine receptor (Ryr). Fluorescence resonance energy transfer between an FKBP bound to an RyR and fluorescent derivatives of RyR binding partners (e.g., calmodulin) or domain-peptide biosensors is used to provide a readout dependent on the RyR functional state. The methods permit measurement of RyR present in a permeabilized cell or in a purified membrane.
Owner:RGT UNIV OF MINNESOTA +1
Fusion protein comprising an e. coli chaperone protein and a human chaperone protein
ActiveUS20110189754A1Superior folding helper activityHigh activitySugar derivativesEnzyme stabilisationEscherichia coliNucleotide
The invention discloses the cloning, expression and uses of a chimeric fusion protein with superior chaperone and folding activities compared to the wild type chaperones. This invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule containing nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for an FK506 binding protein (FKBP) or an FK506-binding-protein-like domain (FKBP-like domain). In particular, this invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule containing nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for a human FKBP type peptidyl-prolyl-cis / trans isomerase (PPIase), methods of producing these chimeric fusion proteins and their uses as folding helpers in the production of other proteins and in the process of the production of vaccines or pharmaceuticals, and as folding helpers for performing immunoassays.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Use of fkbp-l polypeptides and nucleic acids for the treatment of obesity
ActiveUS20190247462A1High activityImprove the level ofPeptide/protein ingredientsMetabolism disorderDiseaseFKBP
The inventors have determined that increasing the expression level or activity of FKBP-L polypeptide in a subject, which can be provided by expression of nucleic acids encoding FKBP-L or by providing FKBP-L polypeptides to a subject is advantageous for use in the treatment of obesity and obesity-related disorders. In particular increased expression or activity of FKBP-L polypeptide in a subject may be used to treat excessive weight gain (which can be characterised as obesity), glucose intolerance, diabetes and metabolic syndrome, which are closely linked to obesity and insulin resistance. FKBP-L can also be used as a biomarker for obesity and obesity-related disorders.
Owner:ROYAL COLLEGE OF SURGEONS & IRELAND
Methods and reagents for analyzing protein-protein interfaces
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of thecyclophilin family, or PIN1) and a target protein. In some embodiments, the target and / or presenter proteins are intracellular proteins. In some embodiments, the target and / or presenter proteins are mammalian proteins.
Owner:REVOLUTION MEDICINES INC
Fkbp binding composition and pharmaceutical use thereof
A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I,wherein, R, R1, R2, R3 and X are as defined herein.
Owner:AVENTISUB LLC
Rapamycin analogues and their pharmaceutical use
Novel rapamycin analogues and methods for their production with FKBP and / or MIP inhibitory activity with reduced mTOR inhibitory activity with therapeutic potential e.g. as bacterial virulence inhibitors.
Owner:ISOMERASE THERAPEUTICS
FK506 compound/FKBP protein dimer containing pharmaceutical composition and preparation method thereof
InactiveCN106074367ASolve the following shortcomingsImprove solubilityOrganic active ingredientsSenses disorderFKBPSolubility
The invention discloses an FK506 compound / FKBP protein dimer containing pharmaceutical composition and a preparation method thereof. FK506 and hFKBP12a protein in the FK506 compound / FKBP protein dimer containing pharmaceutical composition are combined according to a mass ratio of 1:1, and a PBS buffer solution with pH being 6-8 serves as a solvent. A dimer formed by FK506 and endogenous binding protein hFKBP12a of FK506 can greatly improve solubility of FK506 in a water solution, and accordingly efficacies of an FK506 water solution are enhanced while storage time of the FK506 water solution is prolonged.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
Nano switch molecules and activation control solid tumor targeted CAR-T cells thereof
ActiveCN111358956AAddressing off-target effectsTumor-specificPowder deliveryOrganic active ingredientsTumor targetTumor targeting
The present invention discloses nano switch molecules and activation control solid tumor targeted CAR-T cells thereof. The solid tumor targeted CAR-T cells are prepared by the following steps of 1) preparing the nano switch molecules, wherein switch molecules are loaded on tumor targeted nanoparticles by adopting a double emulsification-volatilization method; 2) constructing assembled CAR-T plasmids, wherein T2A elements, FRB and FKBP sequences and solid tumor targeted ScFv fragments are introduced in CAR-T plasmids by using a genetic recombination method; 3) preparing assembled CAR-T cells, wherein the assembled CAR-T plasmids are transfected with T lymphocytes; and 4) preparing the solid tumor targeted CAR-T cells, wherein the assembled CAR-T cells endocytose the nano switch molecules. The switch molecules are loaded on the tumor targeted nanoparticles, so that the switch molecules can be specifically gathered on the tumor tissues; and FKBP and FRAP of CAR-T are connected by the switch molecules, so that two parts of CAR-T are combined to have the attack activity, and the problem of CAR-T cell off-target effect can be solved fundamentally.
Owner:NANJING DRUM TOWER HOSPITAL
N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof
A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I,wherein, R, R1, R2, R3 and X are as defined herein.
Owner:AVENTISUB LLC
Compounds for treating and preventing exercise-induced cardiac arrhythmias and its preparation method
The present invention provides methods of limiting or preventing decreased levels of RyR2-bound FKBP 12.6 in a patient, methods of treating or preventing exercise-induced cardiac arrhythmias in a patient, and methods of preventing exercise-induced sudden cardiac death in a patient. Use of JTV-519 in these methods is also provided. The present invention also provides a method of identifying a substance for preventing exercise-induced sudden cardiac death, and a substance identified by the method. Also provided are methods of preventing exercise-induced sudden cardiac death by administering these substances. Additionally, the present invention provides methods for the synthesis of JTV-519, radiolabeled JTV-519, and 1,4-benzothiazepine intermediates and derivatives.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Compositions and methods for regulatable antibody expression
PendingUS20190002915A1Organic active ingredientsFusion with DNA-binding domainDNA-binding domainIntravenous gammaglobulin
Compositions containing multiple different AAV stock are provided which allow for regulated expression of an immunoglobulin in a variety of tissues. Also provided is a method for regulating the dose of a pharmacologically active immunoglobulin. The method involves co-administering: (a) a first stock of recombinant AAV containing: an activation domain operably linked to expression control sequences comprising a promoter and a first nuclear localization signal; and a DNA binding domain comprising a zinc finger homeodomain and two or more FK506 binding protein domain (FKBP) subunit genes, wherein a first FKBP subunit gene and a second FKBP subunit gene have coding sequences which are no more than about 85% identical to each other, said DNA binding domain being operably linked to a second nuclear localization signal; and (b) a second stock of recombinant AAV comprising at least 2 to about 12 copies of a zinc finger homeodomain which are specific binding partners for the zinc finger homeodomain of the DNA binding domain, and further comprising at least one immunoglobulin expression cassette operably linked to inducible expression control sequences, such that when an effective amount of a rapamycin or rapalog is delivered transcription and expression of the immunoglobulin gene is induced.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
A nanoswitch molecule and its control of activated solid tumor-targeted CAR-T cells
ActiveCN111358956BAddressing off-target effectsTumor-specificPowder deliveryOrganic active ingredientsFKBPTumor targeting
Owner:NANJING DRUM TOWER HOSPITAL
Fusion protein comprising an E. coli chaperone protein and a human chaperone protein
ActiveUS7947494B2High activityEasy to foldSugar derivativesFusions for enhanced expression stability/foldingChaperoninTGE VACCINE
The invention discloses the cloning, expression and uses of a chimeric fusion protein with superior chaperone and folding activities compared to the wild type chaperones. This invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule comprising nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for an FK506 binding protein (FKBP) or an FK506-binding-protein-like domain (FKBP-like domain). In particular, this invention relates to a chimeric fusion protein encoded by a recombinant DNA molecule comprising nucleotide sequences coding for a polypeptide binding segment of a non-human chaperone protein and nucleotide sequences coding for a human FKBP type peptidyl-prolyl-cis / trans isomerase (PPIase), methods of producing these chimeric fusion proteins and their uses as folding helpers in the production of other proteins and in the process of the production of vaccines or pharmaceuticals, and as folding helpers for performing immunoassays.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Compositions and methods for promoting nerve regeneration
Analogs of FK506 that do not bind FKBP-12 have been found to effectively promote nerve cell growth and regeneration, thereby speeding functional recovery of damaged nervous tissue and axonal regeneration without causing immunosuppression.
Owner:OREGON HEALTH & SCI UNIV
Thermus thermophilus SlyD FKBP domain specific antibodies
The present description relates to anti-Thermus thermophilus SlyD FKBP domain antibodies and methods of using the same.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Use of FKBP-L polypeptides and nucleic acids for the treatment of obesity
ActiveUS11376308B2High activityImprove the level ofPeptide/protein ingredientsMetabolism disorderDiseaseFKBP
The inventors have determined that increasing the expression level or activity of FKBP-L polypeptide in a subject, which can be provided by expression of nucleic acids encoding FKBP-L or by providing FKBP-L polypeptides to a subject is advantageous for use in the treatment of obesity and obesity-related disorders. In particular increased expression or activity of FKBP-L polypeptide in a subject may be used to treat excessive weight gain (which can be characterised as obesity), glucose intolerance, diabetes and metabolic syndrome, which are closely linked to obesity and insulin resistance. FKBP-L can also be used as a biomarker for obesity and obesity-related disorders.
Owner:ROYAL COLLEGE OF SURGEONS & IRELAND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com